Company intelligence / Profile preview

D-10 Therapeutics

Torrance, California, United Statesd10therapeutics.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

Developing a novel therapy for sickle cell disease that prevents damage to blood vessels by blocking receptors that cause sickle cells to adhere to blood vessel walls and inducing relaxation of smooth muscle cells to widen blood vessels

Therapeutic areas: Hematology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

2 assets

D10-mAb1

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

IQVIA (for filing priority pediatric review voucher)

Beyond the preview

Go deeper on D-10 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-10 Therapeutics.

Explore the full profile